Volume 6.21 | Jun 2

Hematopoiesis News 6.21 June 2, 2015
Hematopoiesis News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   HN on Twitter
Developmental-Stage-Dependent Transcriptional Response to Leukemic Oncogene Expression
Scientists studied the differentiation of mouse embryonic stem cells expressing an inducible RUNX1-ETO gene into blood cells as a model, combined with genome-wide analyses of transcription factor binding and gene expression. [Nat Commun] Full Article
Get More of the Cells You Need with StemSpan™ Myeloid Expansion Supplement and StemSpan™ SFEM
PUBLICATIONS (Ranked by impact factor of the journal)
Protracted Dormancy of Pre-Leukemic Stem Cells
Researchers describe the genomics of a rare case of childhood BCR-ABL1 positive, B cell precursor acute lymphoblastic leukemia that relapsed, with an AML immunophenotype, 22 years after the initial diagnosis, sustained remission and presumed cure. [Leukemia] Abstract | Full Article | Press Release

Epigenetic Therapy Restores Normal Hematopoiesis in a Zebrafish Model of NUP98-HOXA9-Induced Myeloid Disease
The authors generated a transgenic zebrafish expressing human NUP98-HOXA9 (NHA9), a fusion oncogene found in high-risk acute myeloid leukemia. They leveraged this model to show that NHA9 increases the number of hematopoietic stem cells, and that oncogenic function of NHA9 depends on downstream activation of meis1, the PTGS/COX pathway, and genome hypermethylation through the DNA methyltransferase, dnmt1. [Leukemia] Abstract

Interleukin-6 Enhances the Activity of In Vivo Long-Term Reconstituting Hematopoietic Stem Cells in “Hypoxic-Like” Expansion Cultures Ex Vivo
Since interleukin-6 synergizes with the physiologically relevant O2 concentration in the maintenance of primitive hematopoietic stem cell (HSC) subpopulations, researchers hypothesized that its addition to their hypoxic response mimicking cultures, composed of an antioxidant-supplied serum-free xeno-free medium supplemented with the cytokines stabilizing hypoxia-inducible factor-1α and balancing HSC self-renewal and commitment, will result in a similar effect even if they are exposed to 20% O2. [Transfusion] Abstract

Mitochondrial Dysfunction in Human Leukemic Stem/Progenitor Cells upon Loss of RAC2
Investigators observed that in BCR-ABL-transduced human hematopoietic stem/progenitor cells depletion of RAC2 but not RAC1 induced a marked and immediate decrease in proliferation, progenitor frequency, cobblestone formation and replating capacity, indicative for reduced self-renewal. [PLoS One] Full Article

Transplantation of Ex Vivo Incubated Bone Marrow with rIL-7 for the Enhancement of Immuno-Hematopoietic Reconstitution
Scientists investigated the efficacy of ex vivo incubated bone marrow cells treated with recombinant human interleukin-7 (rIL-7) on subsequent in vivo murine models of syngeneic bone marrow transplantation. [Leuk Lymphoma] Abstract


Minimal Residual Disease Analysis by Eight-Color Flow Cytometry in Relapsed Childhood Acute Lymphoblastic Leukemia
Investigators addressed evaluation of minimal residual disease by flow cytometry in the clinical trial for childhood relapsed acute lymphoblastic leukemia using an eight-color flow cytometry. [Haematologica]
Abstract | Full Article

Control of Relapsed or Refractory Acute Myeloid Leukemia by Clofarabine in Preparation for Allogeneic Stem Cell Transplantation
Since elimination of the leukemic load is thought to be prerequisite for treatment success, researchers investigated toxicity and anti-leukemic activity of a clofarabine-AraC salvage protocol preceding transplantation. [Leuk Lymphoma] Abstract

Early and Progressive Insulin Resistance in Young, Non-Obese Cancer Survivors Treated with Hematopoietic Stem Cell Transplantation
In a single-center, prospective, descriptive, cross-sectional study, the authors studied 45 survivors of hematological malignancies treated with hematopoietic stem cell transplantation before the age of 18 years and 90 matched healthy controls. They collected clinical, imaging, and laboratory data including oral glucose tolerance test. [Pediatr Blood Cancer] Abstract

It all starts with the right cells! Access a range of fresh and frozen human primary cells.
The Role of CCN Family Genes in Hematological Malignancies
The authors look at the role of the CCN family of matricellular proteins and indicate their role in nine hematological malignancies including both myeloid and lymphoid neoplasms. [J Cell Commun Signal] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
Amphivena Therapeutics Presents Positive Data on Novel Acute Myeloid Leukemia (AML) Immunotherapy
Amphivena Therapeutics, Inc. announced positive data from several preclinical studies characterizing the company’s proprietary T-cell redirecting bispecific CD33/CD3-targeting antibodies as potential immunotherapeutics for the treatment of AML. [Press release from Amphivena Therapeutics, Inc. discussing research presented at the 2015 American Society for Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release

TG Therapeutics Announces the Triple Combination of TG-1101, TGR-1202 and Ibrutinib Is Safe and Highly Active in Patients with Advanced B-Cell Malignancies
TG Therapeutics, Inc. announced clinical results from its ongoing study with TG-1101 (ublituximab), the company’s novel glycoengineered anti-CD20 monoclonal antibody in combination with the company’s oral, once-daily, PI3K delta inhibitor, TGR-1202 and ibrutinib, a BTK inhibitor. [Press release from TG Therapeutics, Inc. discussing research presented at the 2015 American Society for Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release

Amgen to Advance Understanding of the Treatment of Blood Cancers
Amgen announced that it will present data from multiple Kyprolis® (carfilzomib) for injection, BLINCYTO® (blinatumomab), oprozomib and Nplate® (romiplostim)‎ studies. The data reinforce Amgen’s commitment to advancing the care of patients with hematologic malignancies through the development of novel treatment approaches and continued evaluation of marketed products. [Press release from Amgen Inc. discussing research to be presented at the 20th Congress of the European Hematology Association (EHA), Vienna] Press Release

From our sponsor: Learn about applications of ALDHbr cells in regenerative medicine. Watch the video.
bluebird bio and Five Prime Therapeutics Enter into License Agreement for Novel Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy
bluebird bio, Inc. and Five Prime Therapeutics, Inc. announced that they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor T cell therapies using Five Prime’s proprietary human antibodies to an undisclosed cancer target for hematologic malignancies and solid tumors. [bluebird bio, Inc.] Press Release

Pluristem Granted Key Cell Patents in Asia, Russia, Mexico, and Israel
Pluristem Therapeutics Inc. announced it has been granted patents covering cell manufacturing, pharmaceutical compositions and disease treatment in China, South Korea, Mexico, Russia, and Israel. [Pluristem Therapeutics Inc.] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Cell Death
September 15-19, 2015
Cold Spring Harbor, United States

Visit our events page to see a complete list of events in the hematopoiesis community.
NEW Postdoctoral Fellow – Cell Fate Decisions in Normal and Malignant Blood Stem Cells (University of Cambridge)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Head of Stem Cells Immunotherapies Service Lab (NHS Blood and Transplant)

Postdoctoral Fellow – Immune Reconstitution in Hematopoietic Stem Cell Transplantation (Stanford University)

Head of Cellular Therapies Laboratory (NHS Blood and Transplant)

Postdoctoral Fellow – Immune Tolerance (Stanford University)

Postdoctoral Position – Epigenetic Regulation of Hematopoiesis and Leukemia (Karolinska Institute)

Postdoctoral Scientist – Hematopoiesis (University of Oxford)

Postdoctoral Researcher – Hematopoietic Stem Cell Physiology and Pathophysiology (International Research Center for Medical Sciences)

Postdoctoral Associate – Epigenetic Regulation of Normal and Leukemic Stem Cells (Sanford-Burnham Medical Research Institute)

Postdoctoral Fellow – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us